Yesterday, a Director at Genocea Biosciences (NASDAQ: GNCA), George Siber, bought shares of GNCA for $100.2K.
In addition to George Siber, one other GNCA executive reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Currently, Genocea Biosciences has an average volume of 1.16M.
Starting in November 2017, GNCA received 14 Buy ratings in a row.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genocea Biosciences engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses.
